Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,854
datasets available to search
ShareScore release 0.9.0
Dataset results
2,854 results for “hepatocellular carcinoma”
Dataset related to article "Vessels Encapsulating Tumor Clusters (VETC) Is a Powerful Predictor of Aggressive Hepatocellular Carcinoma.
<p>We investigated the clinical significance of a vascular growth pattern of hepatocellular carcinoma (HCC), the vessels that encapsulate tumor clusters (VETC), previously linked to HCC metastatic dissemination. VETC was assessed in a large multi-institutional cohort of 541 resected HCCs from Italy, Korea and Japan, and matched against a full spectrum of clinical and pathological variables. The VETC phenotype (defined as ≥ 55% tumor area by CD34 immunostaining) was easily reproducible and reliably detectable in whole sections and small-sized tissues of tissue microarray. VETC HCCs represented 18.9% of the whole series, the lowest proportion occurring in the cohort with smallest tumors (8.7%, Japanese series). VETC was significantly associated with several clinical and pathological features such as high alfa-fetoprotein (AFP) level, tumor size greater than 5 cm, poor differentiation, macrotrabecular pattern, less compact pattern, less inflammatory infiltrates, and frequent microvascular invasion. VETC was associated with early recurrence (hazard ratio [HR]: 1.52 [1.06-2.19], P = 0.023), disease-free survival (HR: 1.66 [1.21-2.27], P = 0.002), and overall survival (HR: 2.26 [1.37-3.72], P = 0.001) at multivariable analysis. VETC affected the survival in HCC patients stratified for etiology (hepatitis C virus/hepatitis B virus), vascular invasion, and specific molecular phenotypes (β-catenin/GS+). This distinct vascular pattern was enriched in the recently reported macrotrabecular massive HCC subtype, which was seen in 7.8% (42 of 541) of patients and associated with high AFP levels and poor differentiation. Conclusion: The VETC pattern was found to be easily detectable in a consistent fraction of HCC and a powerful pathological finding affecting survival. This study suggests that the heterogeneous pattern of angiogenesis is involved in HCC behavior.</p>
Dataset related to article "Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors"
<p>This record contains raw data related to article "Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors"</p> <p>Risk factors for hepatic immune-related adverse events (HIRAEs) in patients with advanced/unresectable hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs) are unclear. We investigated: (i) clinical and morpho-pathological predictors of HIRAEs in 27 pretreatment tumor specimens, including surrogate biomarkers of the HCC immune class (based on intratumoral tertiary lymphoid structures, and glutamine synthase, CD3, and CD79 expression); and (ii) the relationship between HIRAE onset and subsequent treatment outcomes. Fifty-eight patients were included-20 (34%) received ICIs alone, and 38 (66%) received ICIs plus targeted agents as first- or further-line treatment. After a median time of 0.9 months (range, 0.4-2.7), nine patients (15.5%) developed grade ≥ 3 hepatitis, which was significantly associated with higher baseline ALT levels (<em>p</em> = 0.037), and an infectious HCC etiology (<em>p</em> = 0.023). ICIs were safely resumed in six out of nine patients. Time to treatment failure (TTF) was not significantly different in patients developing grade ≥ 3 hepatitis vs. lower grades (3.25 vs. 3.91 months, respectively; <em>p</em> = 0.81). Biomarker surrogates for the HCC immune class were not detected in patients developing grade ≥ 3 hepatitis. Grade ≥ 3 hepatitis has a benign course that does not preclude safe ICI reintroduction, without any detrimental effect on TTF.</p>
Dataset related to article "Prognostic Value of Metabolic Imaging Data of 11 C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma "
<p>This record contains raw data related to article “Prognostic Value of Metabolic Imaging Data of <sup>11</sup> C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma"</p> <p><sup>11</sup>C-choline positron emission tomography/computed tomography (PET/CT) has been used for patients with some types of tumors, but few data are available for hepatocellular carcinoma (HCC). We queried our prospective database for patients with HCC staged with <sup>11</sup>C-choline PET/CT to assess the clinical impact of this imaging modality. Seven parameters were recorded: maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), liver standardized uptake value (SUVliver), metabolic tumor volume (MTV), photopenic area, metabolic tumor burden (MTB = MTVxSUVmean), and SUVratio (SUVmax/SUVliver). Analysis was performed to identify parameters that could be predictors of overall survival (OS). Sixty patients were analyzed: fourteen (23%) were in stage 0-A, 37 (62%) in stage B, and 9 (15%) in stage C of the Barcelona classification. The Cox regression for OS showed that Barcelona stages (HR = 2.94; 95%CI = 1.41-4.51; <em>p</em> = 0.003) and MTV (HR = 2.11; 95%CI = 1.51-3.45; <em>p</em> = 0.026) were the only factors independently associated with OS. Receiver operating characteristics curve analysis revealed MTV ability in discriminating survival (area under the curve (AUC) = 0.77; 95%CI = 0.57-097; <em>p</em> < 0.001: patients with MTV ≥ 380 had worse OS (<em>p</em> = 0.015)). The use of <sup>11</sup>C-choline PET/CT allows for better prognostic refinement in patients undergoing hepatectomy for HCC. Incorporation of such modality into HCC staging system should be considered.</p>
Dataset related to article "Critical appraisal of the potential role of intensity modulated proton therapy in the hypofractionated treatment of advanced hepatocellular carcinoma"
<p>This record contains raw data related to article "Critical appraisal of the potential role of intensity modulated proton therapy in the hypofractionated treatment of advanced hepatocellular carcinoma"</p> <p>PURPOSE:</p> <p>To investigate the role of intensity modulated proton therapy (IMPT) for advanced hepatocellular carcinoma in comparison with volumetric modulated arc therapy (VMAT).</p> <p>METHODS:</p> <p>An in-silico planning study was performed on 20 patients. The prescription dose was 60Gy in 6 fractions. Patients were planned with abdominal compression. IMPT plans were optimized with or without the inclusion of CT calibration (3%) and isocenter positioning (2,4,6mm) uncertainties. Plan robustness was appraised comparing rubust optimized plans vs standard plans and also in terms of the worst-case scenario. VMAT plans were optimized for 10FFF photon beams using 2 partial arcs.</p> <p>RESULTS:</p> <p>Target coverage was fully achieved by both VMAT and IMPT plans with a significant improvement in homogeneity (~25%) with IMPT. Integral dose was reduced of ~60% with IMPT while the conformality of the dose distributions was similar among techniques. The sparing of the organs at risk was strongly improved with IMPT although all clinical objectives were met for both techniques. The inclusion of the uncertainties in the optimization lead to some deterioration in the target dose homogeneity (from 40 to 80% worse with 4 or 6mm position uncertainty) while none of the coverage parameters or OAR objective was violated. The worst-case scenario analysis demonstrated the risk of a major target underdosage only in the case of the most extreme errors (6mm) with D98% in average ~12% lower than the threshold.</p> <p>CONCLUSION:</p> <p>IMPT with the support of abdominal compression, can be considered a viable solution also for advanced hepatocellular carcinoma patients. Great care shall be put in the minimization of the residual respiration and positioning uncertainties but the dosimetric advantage for organs at risk and the relative robustness on target coverage are promising factors.</p> <p> </p>
Validation and Enhancement of the IMbrave050 Criteria: Liver Stiffness Measurement for High-Risk Recurrence and Adjuvant Treatment of Hepatocellular Carcinoma
Open the record for dataset details and reuse information.
N6-Methyladenosine Reader YTHDF3-Mediated CEBPA Translation Maintains Genomic Stability and Stem Cells Function to Prevent Liver Injury and Hepatocellular Carcinoma [RIP-seq]
GEO Series GSE259225. Mus musculus. 12 samples. Type: Other.
Exon- expression data of Human hepatocellular carcinoma cells ( CD90 + HSP90 + HCC cells )
GEO Series GSE215984. Homo sapiens. 2 samples. Type: Expression profiling by array.
Preliminary investigation of the effect of transfected HBx on the expression pattern of circRNAs in hepatocellular carcinoma
GEO Series GSE186884. Homo sapiens. 2 samples. Type: Non-coding RNA profiling by high throughput sequencing.
N6-methyladenosine reader YTHDF1 promotes stemness and therapeutic resistance in hepatocellular carcinoma by enhancing NOTCH1 expression
GEO Series GSE252752. Homo sapiens. 22 samples. Type: Expression profiling by high throughput sequencing; Other.
Proteomic characteristics of mesenchymal subtypes of hepatocellular carcinoma
GEO Series GSE199141. Homo sapiens. 113 samples. Type: Protein profiling by protein array.
Expression data from tumor-associated endothelial cells of hepatocellular carcinoma
GEO Series GSE51401. Homo sapiens. 64 samples. Type: Expression profiling by array.
RFX8-mediated Transcriptional Activation of DDX24 Promotes Hepatocellular Carcinoma Via LAMB1/SRC Signaling [RNA-seq]
GEO Series GSE145635. Homo sapiens. 3 samples. Type: Expression profiling by high throughput sequencing.
RFX8-mediated Transcriptional Activation of DDX24 Promotes Hepatocellular Carcinoma Via LAMB1/SRC Signaling
GEO Series GSE145636. Homo sapiens. 7 samples. Type: Expression profiling by high throughput sequencing.
Notch activity determines a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features [Venus]
GEO Series GSE154550. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
Targeting non-junctional Claudin-1 with monoclonal antibodies to treat hepatocellular carcinoma
GEO Series GSE196393. Homo sapiens. 33 samples. Type: Expression profiling by high throughput sequencing.
LncRNA profile of human liver tissues: hepatocellular carcinoma vs. matched noncancerous liver tissue
GEO Series GSE72170. Homo sapiens. 400 samples. Type: Non-coding RNA profiling by array.
S100A9 from tumor-associated macrophage enhances cancer stem cell-like properties of hepatocellular carcinoma
GEO Series GSE158792. Homo sapiens. 4 samples. Type: Expression profiling by array.
The role of CMTM4 in hepatocellular carcinoma
GEO Series GSE186815. Homo sapiens. 6 samples. Type: Expression profiling by array.
Gene expression accompanying the promotion of hepatocellular carcinoma by intestinal microbiota and Tlr4 in mice.
GEO Series GSE30485. Mus musculus. 15 samples. Type: Expression profiling by array.
Proteomic analysis of pervanadate-induced tyrosine-phosphorylated proteins in hepatocellular carcinoma WRL 68 cells
GEO Series GSE2408. Homo sapiens. 1 samples. Type: Other.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.